Abstracts tagged "B-Cell Targets"

Abstract Number: LB04 • ACR Convergence 2025
Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug Free Remission in Refractory Autoimmune Diseases
Huihua Ding¹, Wensi Li², Yiwen Shen³, Chunyan Zhang⁴, Yan Ye³, Ran Wang³, Shaoying Yang³, Chunmei Wu³, Dai Dai³, Chengxiao Zheng², Yuan Qian², Xiaobing Luo⁵, Thule Trinh⁵, Judy Zhu², Jiaqi Huang⁵, Yong Hao³, Xiaoying Yao³, Zhenfen Ling⁶, Yihong Yao⁵ and Nan Shen¹, ¹Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ²Shanghai AbelZeta Ltd., Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China, ⁵AbelZeta Inc., Rockville, ⁶Shanghai General Hospital, Shanghai, China (People's Republic)
Background/Purpose: Refractory autoimmune diseases with progressive organ damage remain a major unmet medical need. C-CAR168 is an autologous anti-CD20/BCMA bispecific CAR-T therapy designed to simultaneously…
Abstract Number: LB13 • ACR Convergence 2025
Obinutuzumab Leads to Deep B-Cell Depletion in the Kidney Parenchyma of Patients With Lupus Nephritis: An Exploratory Analysis of the REGENCY Trial
Brad Rovin¹, Elsa Martins², Cary Austin³, Harini Raghu³, Caleb Chan³, Patrick Chang³, Jay Garg³, Valeria Alberton⁴, Mittermayer Santiago⁵, Gustavo Aroca-Martínez⁶, Fedra Palazuelos⁷, Teresa Baczkowska⁸, José Alfaro⁹, Jorge Ravelo-Hernández¹⁰, Richard Furie¹¹, Luís Pinto¹², Eduardo Albiero¹³, Christopher Larsen¹⁴, Bongin Yoo³, Jennifer Pulley¹⁵, Andrew Thorley³, Thomas Schindler², Theodore Omachi³, William Pendergraft III³ and Ana Malvar¹⁶, ¹Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, ²F. Hoffmann-La Roche Ltd, Basel, Switzerland, ³Genentech, Inc., South San Francisco, California, ⁴Pathology Unit, Fernández Hospital, Buenos Aires, Argentina, ⁵Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Brazil, ⁶Universidad Simón Bolívar y Clínica de la Costa, Barranquilla, Colombia, ⁷Centro de Investigación y Tratamiento Reumatológico S.C., Mexico City, Mexico, ⁸Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ⁹Instituto Peruano del Hueso y la Articulación, Lima, Peru, ¹⁰Clinica San Juan Bautista, Unidad de Investigacion en Reumatologia e Inmunologia, Lima, Peru, ¹¹Division of Rheumatology, Northwell Health, Great Neck, New York, ¹²Internal Medicine and Rheumatology, Hospital Pablo Tobón Uribe, Medellín, Colombia, ¹³Sanatorio Allende, Córdoba, Argentina, ¹⁴Arkana Laboratories, Little Rock, Arkansas, ¹⁵Roche Products Ltd, Welwyn Garden City, United Kingdom, ¹⁶Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: B cells infiltrate the kidneys in lupus nephritis (LN) and likely contribute to the pathogenesis of kidney injury. The REGENCY trial (NCT04221477) showed that…
Abstract Number: LB14 • ACR Convergence 2025
Promising Early Outcomes With BMS-986353, a CD19-directed Chimeric Antigen Receptor T Cell Therapy in Severe Refractory Idiopathic Inflammatory Myopathies: Safety and Efficacy Findings From the Ongoing Phase 1 Trial
Rohit Aggarwal¹, David Korman², Margrit Wiesendanger³, Vikas Majithia⁴, Ellen De Langhe⁵, Marc Schmalzing⁶, Melissa Griffith⁷, Philipp Koehler⁸, Joanna Schiller⁸, Dimitrios Mougiakakos⁹, Mohamad Cherry¹⁰, Richard Nash¹¹, Jacques Azzi¹², Ernesto Ayala⁴, Peter Vandenberghe⁵, Max Topp⁶, Jonathan Gutman⁷, Eugen Feist¹³, Alisha Desai¹⁴, Alexis Melton¹⁴, Alice Wozniak¹⁴, San-San Ou¹⁴, Melissa Harnois¹⁴, Jerill Thorpe¹⁴, Praneeth Jarugula¹⁴, Takafumi Ide¹⁴, Ashley Koegel¹⁴ and Neil Kramer¹⁵, ¹University of Pittsburgh, Pittsburgh, Pennsylvania, ²Mountain Rheumatology, HCA HealthONE, Denver, Colorado, ³Icahn School of Medicine at Mount Sinai, New York, New York, ⁴Mayo Clinic Hospital, Jacksonville, Florida, ⁵University Hospitals Leuven, Leuven, Belgium, ⁶University Hospital Würzburg, Würzburg, Germany, ⁷University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁸University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Division of Clinical Immunology and Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, Cologne, Germany, ⁹University Hospital Magdeburg, Magdeburg, Germany, ¹⁰Atlantic Health System, Morristown, New Jersey, ¹¹HealthOne Cares and Colorado Blood Cancer Institute, Denver, Colorado, ¹²Icahn School of Medicine at Mount Sinai Hospital, New York, New York, ¹³Helios Vogelsang-Gommern Specialist Clinic, Gommern, Germany, ¹⁴Bristol Myers Squibb, Princeton, New Jersey, ¹⁵Overlook Medical Center and Atlantic Medical Group, Atlantic Health System, Morristown, New Jersey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are systemic autoimmune diseases affecting muscles, skin, lungs, joints, and several other organs; many patients are refractory to available therapy,…
Abstract Number: LB18 • ACR Convergence 2025
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
Rita Pozovskiy¹, Yemil Atisha-Fregoso² and Betty Diamond³, ¹Zucker School of Medicine, New York, New York, ²Feinstein Institutes for Medical Research, New York, New York, ³The Feinstein Institutes for Medical Research, Manhasset, New York
Background/Purpose: In systemic lupus erythematosus (SLE), IgG antibodies that target nuclear antigens (ANA) are pathogenic and part of the diagnostic criteria for SLE. Healthy individuals…
Abstract Number: 2669 • ACR Convergence 2025
RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies
Erin Wilfong¹, Tahseen Mozaffar², Elie Naddaf³, Nizar Chahin⁴, Huifang Lu⁵, Iazsmin Bauer Ventura⁶, Courtney Little⁷, Carl diCasoli⁷, Claire Miller⁸, Jenell Volkov⁷, Daniel Nunez⁷, Thomas Furmanak⁷, Jason Stadanlick⁷, Larissa Ishikawa⁷, Zachary Vorndran⁷, Alexandra Ellis⁷, Jazmean Williams⁷, Steve Flanagan⁷, Quynh Lam⁸, Fatemeh Hadi-Nezhad⁸, Raj Tummala⁸, Samik Basu⁷ and David Chang⁹, ¹Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, ²University of California, irvine, Orange, CA, ³Mayo Clinic, Rochester, MN, ⁴Oregon Health & Science University, Portland, ⁵UT MD Anderson Cancer Center, Houston, TX, ⁶University of Chicago, Chicago, IL, ⁷Cabaletta Bio, Philadelphia, PA, ⁸Cabaletta Bio, Philadelphia, ⁹Cabaletta Bio, Bryn Mawr, PA
Background/Purpose: The goals of treatment for idiopathic inflammatory myopathy (IIM) are to eliminate or reduce inflammation, restore muscle performance, reduce morbidity, and improve a patient’s…
Abstract Number: 2293 • ACR Convergence 2025
CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
Ella Ioffe, Karsten Sauer, Todd Shearer, Jennifer Michaelson, Jeffrey Jones, Yue Zhang, Stephen Wax and Antoine Sreih, Cullinan Therapeutics Inc, Cambridge, MA
Background/Purpose: Treatments depleting CD19-expressing B cells have shown benefit in a range of autoimmune diseases. T cell engagers (TCE) offer off-the-shelf convenience, the predictable pharmacokinetic/pharmacodynamic…
Abstract Number: 1525 • ACR Convergence 2025
Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment
Md Yuzaiful Md Yusof¹, Junaid Patel², Paul Emery³ and Ed Vital³, ¹University of Leeds, Leeds, United Kingdom, ²University of Leeds, Leeds, ³University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Emerging therapies such as CD19 CAR-T-cells have been reported to induce deeper B-cell depletion and thereby drug-free remission up to 18 months. With rituximab,…
Abstract Number: 0908 • ACR Convergence 2025
E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease
Hrishikesh Mehta¹, Vijayashree Mysore¹, Chih-Hsing Chou¹, Lizhi Cao¹, Rui Liu², Tianrui Fan², Jijun Yuan², James Broderick¹ and Li Peng¹, ¹Palleon Pharmaceuticals, Waltham, MA, ²Shanghai Henlius Biotech, Shanghai, China (People's Republic)
Background/Purpose: Abnormal cell surface glycosylation has been observed in various autoimmune diseases, including systemic lupus erythematosus (SLE) and membranous nephropathy. Among these glycan modifications, sialoglycans…
Abstract Number: 0236 • ACR Convergence 2025
Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease
Laura Bucci¹, Sebastian Böltz¹, Melanie Hagen¹, Danae-Mona Nöthling¹, Tobias Rothe², Carlo Tur¹, Andreas Wirsching¹, Janina Auth³, jochen wacker¹, Markus Eckstein⁴, Stefano Alivernini⁵, Aline Bozec¹, Christina Bergmann¹, Maria Antonietta D'Agostino⁶, Maria Gabriella Raimondo¹, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: T cell engagers (TCEs) are a promising therapeutic strategy to treat autoimmune diseases (AID). However, long-term data remain limited.Methods: Patients with treatment-refractory AID were…
Abstract Number: 0001 • ACR Convergence 2025
ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
Gang Bian¹, Tengteng Li¹, Huiling Liu², Zaoshun Hu², Peng Chen¹, Jay Mei³ and Bing Hou³, ¹Shanghai Antengene Corporation Limited, Shanghai, China (People's Republic), ²Antengene (Hangzhou) Biologics, Hangzhou, Zhejiang, China (People's Republic), ³Antengene Corporation, Shanghai, China (People's Republic)
Background/Purpose: CD19-targeted therapies, such as chimeric antigen receptor (CAR)-T or T-cell engagers (TCE), have been approved for the treatment of B cell malignancies. By depleting…
Abstract Number: 2665 • ACR Convergence 2025
Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline
Thomas Dörner¹, Nan Shen², Thomas Grader-Beck³, Caroline Walter⁴, Catherine Wioland⁴, Celine Rauld⁴, Patrick Schmutz⁴, Simone Riek⁴, Wolfgang Hueber⁵, CAROLE SIPS⁶, Stephen Oliver⁴, Carol Lau⁷, Claire Bonal⁶ and Isabelle Isnardi⁸, ¹Charite Universitétsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ²Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), ³Johns Hopkins, Reisterstown, MD, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, ⁸Novartis, Gueberschwihr, France
Background/Purpose: Ianalumab, an afucosylated mAb, depletes B cells via enhanced antibody (Ab)-dependent cellular cytotoxicity and blocks B cell-activating factor (BAFF): BAFF-receptor (BAFF-R) mediated signals.1 It…
Abstract Number: 2020 • ACR Convergence 2025
Inebilizumab Efficacy and Safety in Patients with Common, Urgent, and Fibrotic Organ Manifestations of IgG4-RD: Subgroup Analyses from the MITIGATE Trial
Arezou Khosroshahi¹, Emma Culver², Wen Zhang³, Kazuichi Okazaki⁴, Yoshiya Tanaka⁵, Matthias Lohr⁶, nicolas schleinitz⁷, Xinxin Dong⁸, Sue Cheng⁸, Daniel Cimbora⁸ and John Stone⁹, ¹Emory University, Atlanta, GA, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁴Kansai Medical University Kori Hospital, Osaka, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Aix Marseille university, AP-HM, Marseille, France, ⁸Amgen, Thousand Oaks, CA, ⁹Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a progressive, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
Abstract Number: 1517 • ACR Convergence 2025
The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters
Aijing Liu¹, Fei Chang² and Qiuhong Xu¹, ¹Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), ²Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic)
Background/Purpose: Lupus nephritis (LN), affects 30%-50% of systemic lupus erythematosus (SLE) patients, a major contributor to SLE-related mortality. Telitacicept, an innovative recombinant fusion protein, disrupts…
Abstract Number: 0907 • ACR Convergence 2025
Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling
Karel Van Damme¹, Dorine Sichien², Katrien Van der Borght³, Sofie Van Gassen³, Elisabeth De Leeuw³, Victor Bosteels⁴, Joseph Jorssen⁵, Seppe De Winter⁶, Alan Korman⁷, Fabio Benigni⁸, Davide Corti⁸, Ariane Morel⁹, Eric Vivier⁹, Hamida Hammad³, Dirk Elewaut¹⁰, Fabiane Sonego¹¹, Kader Thiam¹¹, Sofie Voet², bianca Balbino¹² and Bart Lambrecht³, ¹Ghent University, Ghent, ²argenx, Ghent, Belgium, ³Ghent University, Ghent, Belgium, ⁴The Francis Crick Institute, London, United Kingdom, ⁵Liège Université, Liege, Belgium, ⁶KU Leuven, Leuven, Belgium, ⁷Vir Biotechnology, San Francisco, ⁸Vir Biotechnology, Bellinzona, Switzerland, ⁹Innate Pharma, Marseille, France, ¹⁰VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ¹¹genOway, Lyon, France, ¹²argenx, Gent, Belgium
Background/Purpose: Fc receptors mediate the effector functions of antibodies by linking adaptive and innate immunity. Immunoglobulin G (IgG), the most abundant antibody in circulation and…
Abstract Number: 0135 • ACR Convergence 2025
Rituximab in Antiphospholipid Syndrome: aPL Titer Decline and Clinical Outcomes
Omer Uludag¹, Soner Altın², Gamze Kemec², yasemin yalcinkaya³, Ahmet Gul³, Murat Inanc³ and Bahar Artim Esen⁴, ¹Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ⁴Istanbul University, Istanbul, Istanbul, Turkey
Background/Purpose: Rituximab treatment has been shown to be effective in non-thrombotic manifestations of APS and refractory catastrophic APS (CAPS). However, there are conflicting results regarding…

1
2
3
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].